AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01059643
Drug: pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
Trial: NCT00431184
Drug: Pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arms description
Trial: NCT00431184
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arms description
Trial: NCT03185143
Drug: Sumatriptan 100 mg
RxNorm normalized name: sumatriptan 100 MG
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Trial: NCT02151084
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02151084
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02151084
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00653185
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Trial: NCT00653185
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Trial: NCT00653185
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Trial: NCT00653185
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Trial: NCT00246337
Drug: Rizatriptan
RxNorm normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rizatriptan 10 mg; one orally-administered dose
Trial: NCT00494533
Drug: Remodulin (treprostinil sodium)
RxNorm normalized name: treprostinil Injectable Solution [Remodulin]
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00403650
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
Trial: NCT03640481
Drug: Belumosudil (KD025)
RxNorm normalized name: belumosudil
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Trial: NCT01226511
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00444743
Drug: MM-093
RxNorm normalized name: MM-093
DrugBank: MM-093 (DB05512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg, administered subcutaneously, weekly
Trial: NCT04082598
Drug: Amoxicillin Clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
Trial: NCT01686152
Drug: Imiquimod Cream, 3.75%
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03593421
Drug: synthetic PreImplantation Factor
RxNorm normalized name: Synthetic PreImplantation Factor
DrugBank: Preimplantation factor (DB16301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peptide
Trial: NCT03285503
Drug: Aripiprazole IM Depot
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
Trial: NCT02174913
Drug: Target controlled infusion of propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
Trial: NCT02174913
Drug: Atracurium
RxNorm normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation
Trial: NCT00332852
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day - oraly
Trial: NCT00439218
Drug: sodium phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
Trial: NCT00435435
Drug: Acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01105702
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01105702
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01105702
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005625
Drug: trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03063021
Drug: N-Acetyl Cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets of N-acetyl-cysteine
Trial: NCT00010959
Drug: Cimicifuga racemosa
RxNorm normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00010959
Drug: Trifolium pratense
RxNorm normalized name: TRIFOLIUM PRATENSE LEAF
DrugBank: Trifolium pratense pollen (DB15530)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01428583
Drug: oxycodone HCl and naltrexone HCl extended-release capsules
RxNorm normalized name: naltrexone hydrochloride / oxycodone hydrochloride Extended Release Oral Capsule
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Trial: NCT01765855
Drug: Betrixaban single oral dose
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02546791
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00000207
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02612480
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
Trial: NCT02612480
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
Trial: NCT00215371
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03262740
Drug: BMS-986195
RxNorm normalized name: BMS-986195
DrugBank: Branebrutinib (DB15347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of specified dose on specified days
Trial: NCT03262740
Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Contraceptive
Trial: NCT00286117
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00286117
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00638456
Drug: Budesonide plus Prevacid
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Trial: NCT03945084
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy
Trial: NCT02319707
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
Trial: NCT02319707
Drug: Oxytocin in 100 ml NaCl 0.9%
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
Trial: NCT01962402
Drug: lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
Trial: NCT00673088
Drug: Ropinirole Hydrochloride
RxNorm normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Restless Leg Syndrome
Trial: NCT03316170
Drug: NRT Sampling
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail.
Trial: NCT05085106
Drug: Felbinac trometamol eye drop
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Trial: NCT04874142
Drug: YYC506-T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single administration
Trial: NCT04874142
Drug: YYC506-T + YYC506-A
RxNorm normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concomotant administration
Trial: NCT04874142
Drug: YYC506-A + YYC506-T
RxNorm normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concomotant administration
Trial: NCT04601103
Drug: High SLS toothpaste
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than or equal to X ppm Sodium Lauryl Sulfate
Trial: NCT00578344
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
Trial: NCT02165202
Drug: Rilpivirine
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
Trial: NCT00188812
Drug: donepezil hcl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01836523
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Trial: NCT00690313
Drug: Vigamox
RxNorm normalized name: Vigamox
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops 3 times day either 1 or 3 days prior to intravitreal injection
Trial: NCT03607851
Drug: Lacosamide - conventional titration
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
Trial: NCT03607851
Drug: Lacosamide - rapid titration 1
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
Trial: NCT03607851
Drug: Lacosamide - rapid titration 2
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
Trial: NCT01640288
Drug: Perfluorinated Gas/Oxygen Mixture
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
Trial: NCT01005602
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
Trial: NCT02814409
Drug: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
RxNorm normalized name: Tissue plasminogen activator alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
Trial: NCT02814409
Drug: Intravenous Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
Trial: NCT00667953
Drug: Gleevec
RxNorm normalized name: Gleevec
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gleevec (600 mg) daily.
Trial: NCT00667953
Drug: Temodar
RxNorm normalized name: Temodar
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
Trial: NCT00091728
Drug: Depo Medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00091728
Drug: Combined oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01544894
Drug: Raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/d for one year
Trial: NCT01544894
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 2 g/d, for one year
Trial: NCT01527643
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
Trial: NCT00996242
Drug: L-lysine
RxNorm normalized name: L-Lysine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 g/day for four weeks
Trial: NCT01444404
Drug: AMG 820
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
Trial: NCT02414594
Drug: IONIS-APO(a)-LRx
RxNorm normalized name: IONIS-APO(a)-LRx
DrugBank: Pelacarsen (DB16284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
Trial: NCT02414594
Drug: Sterile Normal Saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated volume to match active comparator
Trial: NCT00689637
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin: single dose on day 6
Trial: NCT00973414
Drug: Six percent hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
Trial: NCT02416102
Drug: Losartan 50 mg
RxNorm normalized name: losartan 50 mg oral tablet
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg Losartan taken orally once daily for 4 consecutive weeks.
Trial: NCT02416102
Drug: Losartan 100 mg
RxNorm normalized name: losartan 100 mg oral tablet
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg Losartan taken orally twice daily for 4 consecutive weeks.
Trial: NCT01558999
Drug: High concentration SI-614
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye 4 times a day
Trial: NCT01558999
Drug: Low concentration SI-614
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye 4 times a day
Trial: NCT01993459
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
Trial: NCT03520595
Drug: Placebo pills and distilled water 3 pills,3 times daily
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Trial: NCT00212381
Drug: di indolylmethane (DIM)
RxNorm normalized name: di-isopropylammonium
DrugBank: 3,3'-diindolylmethane (DB11875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the agent being studies. Similar agents have been reported to have potential activity.
Trial: NCT01856712
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
Trial: NCT01321541
Drug: Pixantrone + Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
Trial: NCT01321541
Drug: Gemcitabine + Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
Trial: NCT00509236
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg (one 25-mg tablet) once daily
Trial: NCT00509236
Drug: Glipizide
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg